Results 11 to 20 of about 30,994 (308)

GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology

Peptides
Surprisingly, agonists, as well as antagonists of the glucose-dependent insulinotropic polypeptide receptor (GIPR), are currently being used or investigated as treatment options for type 2 diabetes and obesity - and both, when combined with glucagon-like peptide 1 receptor (GLP-1R) agonism, enhance GLP-1-induced glycemia and weight loss further.
Rosenkilde, Mette Marie, Lindquist, Peter, Kizilkaya, Hüsün Sheyma, Gasbjerg, Lærke Smidt   +3 more
openaire   +4 more sources

Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice

Molecular Metabolism, 2017
Objective: Glucose-dependent insulinotropic polypeptide (GIP) is released during meals and promotes nutrient uptake and storage. GIP receptor knockout mice are protected from diet induced weight gain and thus GIP antagonists have been proposed as a ...
Nobuya Inagaki, Norio Harada, Akiko Sankoda   +2 more
exaly   +3 more sources

Glucose-dependent insulinotropic polypeptide (GIP)

Molecular Metabolism
Background Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has
Timo Müller, Matthias Tschoep, Ricardo Samms   +2 more
exaly   +2 more sources

Stimulating intestinal GIP release reduces food intake and body weight in mice

Molecular Metabolism
Objective: Glucose dependent insulinotropic polypeptide (GIP) is well established as an incretin hormone, boosting glucose-dependent insulin secretion.
Jo E. Lewis, Danae Nuzzaci, Paula-Peace James-Okoro, Mireia Montaner, Elisabeth O'Flaherty, Tamana Darwish, Marito Hayashi, Stephen D. Liberles, David Hornigold, Jacqueline Naylor, David Baker, Fiona M. Gribble, Frank Reimann   +12 more
doaj   +2 more sources

Association between plasma glucose-dependent insulinotropic polypeptide and active adiponectin in normoglycemic women [PDF]

Endocrine Connections
Background/objectives: Glucose-dependent insulinotropic polypeptide (GIP) is secreted by enteroendocrine K cells in response to nutrient ingestion. The aims of this study were: i) to evaluate the cross-sectional associations between plasma GIP change in ...
Isidora Salvatierra, Javier Parada, Rodrigo Cataldo, José Eduardo Galgani, Gigliola Alberti, Idoia Labayen, José L Santos   +6 more
doaj   +2 more sources

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354

Frontiers in Pharmacology
Type 2 diabetes (T2D) and obesity are prevalent metabolic disorders affecting millions of individuals worldwide. A new effective therapeutic drug called tirzepatide for the treatment of obesity and T2D is a dual agonist of the GIP receptor and GLP-1 ...
Christopher S Walker, Paul W R Harris, Tayla Rees   +2 more
exaly   +3 more sources

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Cell Metabolism, 2017
Christophe Schmitt, Matthias Tschoep, Richard Dimarchi   +2 more
exaly   +2 more sources

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Cardiovascular Diabetology, 2022
Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin ...
M. Nauck, D. D’Alessio
semanticscholar   +1 more source

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages

Clinical Diabetes, 2023
Unexpected drug shortages of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide emerged in late 2022 and have ...
Heather P. Whitley, Jennifer M. Trujillo, J. Neumiller   +2 more
semanticscholar   +1 more source

Obesity without diabetes: the role of hormonal regulation

Терапевтический архив, 2020
Aim.Obese patients without diabetes present an interesting phenotype to explore protective mechanisms against type 2 diabetes (T2D) development. In our study we looked for specific hormonal features of obese patients without T2D. Materials and methods.
E. A. Shestakova, I. A. Sklyanik, A. S. Panevina, L. V. Nikankina, M. V. Shestakova, I. I. Dedov   +5 more
doaj   +1 more source